Literature DB >> 33399341

Pediatric Mesothelioma With ALK Fusions: A Molecular and Pathologic Study of 5 Cases.

Pedram Argani1,2, Derrick W Q Lian3, Abbas Agaimy4, Markus Metzler5, Sara E Wobker6, Andres Matoso1,2, Jonathan I Epstein1,2, Yun-Shao Sung7, Lei Zhang7, Cristina R Antonescu7.   

Abstract

Pediatric mesotheliomas are rare and their pathogenesis remains undefined. In this study, we report 5 cases of malignant mesothelioma in children, characterized by fusions involving the anaplastic lymphoma kinase (ALK) gene. Four cases occurred in females involving the abdominal cavity and were characterized by a pure epithelioid morphology. The fifth arose in the tunica vaginalis of a 15-year-old male and displayed a biphasic epithelioid-sarcomatoid phenotype. All cases demonstrated the classic morphologic and immunohistochemical features of malignant mesothelioma, including tubulopapillary architecture and cuboidal epithelioid cells with eosinophilic cytoplasm and uniform nuclei with vesicular chromatin. Immunohistochemically, all cases showed labeling for ALK, cytokeratins, WT1, and calretinin, while lacking expression of adenocarcinoma immunomarkers. Four cases demonstrated weak-moderate labeling for PAX8 protein, which resulted in diagnostic challenges with primary peritoneal serous carcinoma. The ALK genetic abnormalities were investigated by a combination of molecular methods. Archer FusionPlex was performed in 2 cases, showing fusions between ALK with either STRN or TPM1 genes, resulting in a transcript that retained the ALK kinase domain. One case was further studied by DNA targeted sequencing, but no additional genetic alterations were observed. In 1 case, cytogenetic analysis showed the presence of a t(2;15)(p23;q22) and fluorescence in situ hybridization confirmed the ALK gene break-apart. In the remaining 2 cases, ALK gene rearrangements were demonstrated by fluorescence in situ hybridization. Unlike adult mesotheliomas, which are tightly linked to asbestos exposure, often show loss of BAP1 expression and have complex karyotypes, ALK-rearranged mesothelioma appears to be similar to other fusion-positive mesotheliomas, such as those harboring EWSR1/FUS-ATF1 fusions, sharing significant morphologic overlap, occurring in young patients and displaying a simple, translocation-driven genetic profile.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33399341      PMCID: PMC8035308          DOI: 10.1097/PAS.0000000000001656

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  40 in total

1.  Malignant peritoneal mesothelioma in a pediatric patient mimicking inflammatory bowel disease.

Authors:  Cynthia Oberto; Kathleen B Schwarz; Elias Zambidis; Andrew B Campbell; Charles Paidas; Kenneth Lindyberg; Maria Oliva-Hemker
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

Review 2.  Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.

Authors:  Rosalind H Gunby; Elisa Sala; Carmen J Tartari; Miriam Puttini; Carlo Gambacorti-Passerini; Luca Mologni
Journal:  Anticancer Agents Med Chem       Date:  2007-11       Impact factor: 2.505

Review 3.  Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.

Authors:  Alfonso García-Fadrique; Akash Mehta; Faheez Mohamed; Sanjeev Dayal; Tom Cecil; Brendan J Moran
Journal:  J Gastrointest Oncol       Date:  2017-10

4.  Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum.

Authors:  Kongsak Loharamtaweethong; Napaporn Puripat; Nadda Aoonjai; Apisada Sutepvarnon; Chanyoot Bandidwattanawong
Journal:  Histopathology       Date:  2015-09-02       Impact factor: 5.087

5.  Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Authors:  Jinfei Xu; Yuwaraj Kadariya; Mitchell Cheung; Jianming Pei; Jacqueline Talarchek; Eleonora Sementino; Yinfei Tan; Craig W Menges; Kathy Q Cai; Samuel Litwin; Hongzhuang Peng; Jayashree Karar; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2014-06-13       Impact factor: 12.701

6.  ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.

Authors:  Leona A Doyle; Adrián Mariño-Enriquez; Christopher D M Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2015-04-10       Impact factor: 7.842

Review 7.  Epidemiologic aspects of childhood mesothelioma.

Authors:  S P Cooper; A E Fraire; P A Buffler; S D Greenberg; C Langston
Journal:  Pathol Immunopathol Res       Date:  1989

8.  Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

Authors:  Giuseppe Bronte; Angelo Delmonte; Marco Angelo Burgio; Alberto Verlicchi; Maurizio Puccetti; Sara Bravaccini; Paola Cravero; Maria Maddalena Tumedei; Danila Diano; Giulio Rossi; Paola Ulivi; Giovanni Martinelli; Lucio Crinò
Journal:  Lung Cancer       Date:  2020-02-14       Impact factor: 5.705

9.  ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.

Authors:  Naoto Kuroda; Kiril Trpkov; Yuan Gao; Maria Tretiakova; Yajuan J Liu; Monika Ulamec; Kengo Takeuchi; Abbas Agaimy; Christopher Przybycin; Cristina Magi-Galluzzi; Soichiro Fushimi; Fumiyoshi Kojima; Malthide Sibony; Jen-Fan Hang; Chin-Chen Pan; Asli Yilmaz; Farshid Siadat; Emiko Sugawara; Pierre-Alexandre Just; Nikola Ptakova; Ondrej Hes
Journal:  Mod Pathol       Date:  2020-05-28       Impact factor: 7.842

10.  A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Authors:  Dina Mönch; Sabine Bode-Erdmann; Jörg Kalla; Jörn Sträter; Carsten Schwänen; Roger Falkenstern-Ge; Siegfried Klumpp; Godehard Friedel; German Ott; Claudia Kalla
Journal:  Oncotarget       Date:  2018-04-17
View more
  5 in total

Review 1.  Pleural mesothelioma classification-update and challenges.

Authors:  Sanja Dacic
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

Review 2.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

Review 3.  When the Diagnosis of Mesothelioma Challenges Textbooks and Guidelines.

Authors:  Giulio Rossi; Fabio Davoli; Venerino Poletti; Alberto Cavazza; Filippo Lococo
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

4.  STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy.

Authors:  Valeria Gerthofer; Alexander Scheiter; Florian Lüke; Felix Keil; Kirsten Utpatel; Laura-Maria-Giovanna Pöhmerer; Johannes Seitz; Christoph Niessen; Atanas Ignatov; Wolfgang Dietmaier; Diego F Calvisi; Matthias Evert; Olaf Ortmann; Stephan Seitz
Journal:  JCO Precis Oncol       Date:  2021-09-16

5.  Malignant Mesothelioma With EWSR1-ATF1 Fusion in Two Adolescent Male Patients.

Authors:  Hezhen Ren; S Rod Rassekh; Atilano Lacson; Cheng-Han Lee; Brendan C Dickson; Catherine T Chung; Anna F Lee
Journal:  Pediatr Dev Pathol       Date:  2021-06-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.